Professor of Medicine (Rheumatology & Yale Cancer Center) Yale University New Haven, Connecticut, United States
Disclosure(s):
Mark Mamula, PhD: TheraJan, LLC: Advisor (Ongoing), TheraJan is a company to develop canine cancer immunotherapy. (Ongoing)
Presentation Description / Summary: Fundamental pathways of immunotherapy as utilized and investigated in both canine and human cancers will be addressed in this presentation. In particular, our Yale laboratories are working on EGFR/HER2 immunotherapy for use in canine cancers. Features of host responses that alter outcomes will be discussed, including tumor microenvironment, microbiome, genomics and mutations, all of which inform the efficacy of various immune therapies. The mechanisms of how immune based therapy, both tumor antigen specific therapies as well as checkpoint inhibitor therapy, will be presented with a focus on the EGFR/HER2 tumor protein family. Finally, the merits of various combination therapies, including chemotherapy and radiation, along side of immunotherapies will be discussed.
Learning Objectives:
Learn the fundamental pathways of immunotherapy, including the rationale of checkpoint inhibition as well as other adoptive and induced immune therapies to tumor associated proteins including the EGFR/HER2 family.
Understand how various host specific parameters may affect efficacy of tumor immunotherapy, including genomics, mutations, microbiome, and tumor microenvironment.
Learn how combined therapies, including radiation and chemotherapy, may improve or alter the efficacy of immunotherapy.
